Additional Information

Description

Inflectra PR 100mg is a biosimilar monoclonal antibody formulation of infliximab designed for intravenous infusion. It is classified as a tumor necrosis factor (TNF) alpha inhibitor, functioning by binding to and neutralizing TNF-alpha, a cytokine involved in systemic inflammation. By inhibiting TNF-alpha, Inflectra helps to modulate inflammatory responses that contribute to autoimmune and chronic inflammatory conditions.

The medication is indicated for the treatment of several inflammatory diseases including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease, and ulcerative colitis. In combination with methotrexate or other immunosuppressants, Inflectra effectively reduces symptoms, improves physical function, and helps prevent further joint or tissue damage in chronic autoimmune disorders.

Inflectra must be reconstituted and administered under the supervision of a healthcare professional trained in managing infusion-related reactions. Potential adverse effects include upper respiratory infections, headache, infusion-related reactions, liver enzyme elevation, and serious infections such as tuberculosis.